Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Observes patients with recurrent or spreading prostate cancer over the long term

Records treatment and disease course in adults with returning or spreading prostate cancer.

Plain-language title generated from the registry record
Registry title: PROCARE - PROstate Cancer Real World Evidence Registry

Key facts

Where
Aachen, Augsburg, Bayenthal, Bayreuth, Bergisch Gladbach, Berlin, Bonn, Braunschweig, Dessau, Duisburg, Düsseldorf, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Giessen, Halle, Hamburg, Heidelberg, Herne, Herzberg am Harz, Hildesheim, Jena, Karlsruhe, Kempten (Allgäu), Leipzig, Lübeck, Magdeburg, Mannheim, Marburg, Neunkirchen, Neustadt am Rübenberge, Nuremberg, Nürtingen, Paderborn, Regensburg, Rostock, Trier, Tübingen, Ulm, Wetzlar, Wilhelmshaven, Wuppertal, Würselen, and Würzburg, GermanySee the 52 sites

Where in Germany

  • University Hospital AachenAachen, GermanyTaking people
  • University Hospital AugsburgAugsburg, GermanyTaking people
  • Medical Office for UrologyBayenthal, GermanyTaking people
  • Hospital Bayreuth GmbHBayreuth, GermanyTaking people
  • Marien Hospital Bergisch Gladbach,Bergisch Gladbach, GermanyTaking people
  • "Vivantes Prostatazentrum" Hospital "am Urban"Berlin, GermanyTaking people
  • Johanniter GmbH, JohanniterkrankenhausBonn, GermanyTaking people
  • Johanniter Hosptal BonnBonn, GermanyTaking people
  • University Hospital BonnBonn, GermanyTaking people
  • Medical Office for UrologyBraunschweig, GermanyTaking people
  • City Hospital DessauDessau, GermanyTaking people
  • Medical Office for Urology "Urologicum"Duisburg, GermanyTaking people
  • University Hospital DüsseldorfDüsseldorf, GermanyTaking people
  • University Hospital ErlangenErlangen, GermanyTaking people
  • University Hospital EssenEssen, GermanyTaking people
  • University Hospital Frankfurt/MainFrankfurt am Main, GermanyTaking people
  • Universitätsklinikum FreiburgFreiburg im Breisgau, GermanyTaking people
  • Universitiy Hospital Gießen und Marburg GmbH, Site: GießenGiessen, GermanyTaking people
  • Universitiy Hospital HalleHalle, GermanyTaking people
  • University Hospital HalleHalle, GermanyTaking people
  • University hospital Hamburg EppendorfHamburg, GermanyTaking people
  • National Center for Tumor Dieseases (NCT) HeidelbergHeidelberg, GermanyTaking people
  • Marien Hospital Herne, University Hospital der Ruhr-Universität BochumHerne, GermanyTaking people
  • Medical Office for UrologyHerzberg am Harz, GermanyTaking people
  • St. Bernward Hospital HildesheimHildesheim, GermanyTaking people
  • St. Bernward Krankenhaus GmbHHildesheim, GermanyTaking people
  • University Hospital JenaJena, GermanyTaking people
  • Urban Hospital KarlsruheKarlsruhe, GermanyTaking people
  • Hospital KemptenKempten (Allgäu), GermanyTaking people
  • University Hospital LeipzigLeipzig, GermanyTaking people
  • Univerity Hospital Schleswig-HolsteinLübeck, GermanyTaking people
  • Medical Office for Urology Altstadtquartier MagdeburgMagdeburg, GermanyTaking people
  • University Hospital MagdeburgMagdeburg, GermanyTaking people
  • Urologie Altstadtquartier MagdeburgMagdeburg, GermanyTaking people
  • University Hospital MannheimMannheim, GermanyTaking people
  • Universital Hospital Gießen & Marburg GmbH, Site: MarburgMarburg, GermanyTaking people
  • Center for Urology BoxbergNeunkirchen, GermanyTaking people
  • MVZ Onco Medical GmbH NeustadtNeustadt am Rübenberge, GermanyTaking people
  • Hospital Nürnberg NorthNuremberg, GermanyTaking people
  • Medical Office for Urology NürtingenNürtingen, GermanyTaking people
  • Studienpraxis UrologieNürtingen, GermanyTaking people
  • "Brüder" Hospital St. Joseph PaderbornPaderborn, GermanyTaking people
  • Caritas Hospital St. JosefRegensburg, GermanyTaking people
  • University hospital RostockRostock, GermanyTaking people
  • Hospital "Barmherzigen Brüder "TrierTrier, GermanyTaking people
  • University Hospital TübingenTübingen, GermanyTaking people
  • University Hospital UlmUlm, GermanyTaking people
  • Hospital WetzlarWetzlar, GermanyTaking people
  • Praxisgemeinschaft f. Onkologie & UrologieWilhelmshaven, GermanyTaking people
  • University Hospital WuppertalWuppertal, GermanyTaking people
  • Medical Office for UrologyWürselen, GermanyTaking people
  • University Hospital WürzburgWürzburg, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
UroTrials Company (GmbH)
Trial code
NCT06835218
Record updated
12 March 2026
Original description
The aim of this registry study with long-term follow-up is to record the course of therapy and disease in patients with recurrent and metastatic prostate cancer. The following patient groups are planned:Read full original descriptionShow less

PROstate CAncer Real World Evidence Registry: RECURRENT AND METASTATIC PROSTATE CANCER

The aim of this registry study with long-term follow-up is to record the course of therapy and disease in patients with recurrent and metastatic prostate cancer. The following patient groups are planned:

* Patients with a recurrence of PSA after surgical removal or radiation of the prostate due to prostate cancer; so-called PSA recurrence (relapse) or biochemical recurrence. * Patients with a PSA recurrence who have received treatment by hormone deprivation therapy (so-called androgen deprivation) and in whom the PSA value has nevertheless risen again without spreading to other organs or parts of the body, so-called non-metastatic castration-resistant prostate cancer. * Patients with proven spread to other organs or parts of the body (= metastases, e.g. in the bone) without hormone deprivation therapy having been initiated, so-called metastatic hormone-sensitive prostate cancer. * Patients with prostate cancer and spread to other organs or parts of the body (= metastases) in whom the tumor disease has progressed despite hormone withdrawal treatment (e.g. as evidenced by an increase in PSA), so-called metastatic castration-refractory prostate cancer.

These four groups of patients are enrolled and observed independently of each other at different time periods.

Inclusion: Adult prostate cancer patients (age ≥18 years); Diagnosis at time of study inclusion Cohort 1: biochemical recurrence (BCR) after local curative intended treatment (e.g. radical prostatectomy, radiotherapy of the prostate or combination thereof) Cohort 2: non-metastatic castration-resistant prostate cancer (nmCRPC) or Cohort 3: metastatic hormone sensitive prostate cancer (mHSPC) or Cohort 4: metastatic castration-resistant prostate cancer (mCRPC) (irrespective of treatment choice, treatment line); Patients who will receive a new line of systemic therapy at the time of study entry or up to 4 weeks thereafter. Regarding Cohort 4 this includes patients with a new diagnosis of mCRPC (=first line mCRPC) after either treatment for mHSPC or non-metastatic CRPC as well as patients with prior mCRPC treatments (2nd, 3rd, … line); For Cohorts 1, 2 and 3: Disease proven by clinical measures (i.e. standard imaging) to be either unsuitable for local salvage treatment (e.g. surgery, radiotherapy) or local treatment is declined by the patient; Patients, who are able and willing to sign the informed consent form.

Exclusion: Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician.

ClinicalTrials.gov NCT06835218